PG324 Ophthalmic Solution 0.02%/0.005%

DRUG2 trials

Sponsors

Aerie Pharmaceuticals

Conditions

Ocular HypertensionOpen-angle Glaucoma

Phase 3

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT02558400

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2015-09-18End: 2017-06-30Updated: 2019-06-04

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

CompletedNCT02674854

Aerie PharmaceuticalsOcular Hypertension, Open-angle Glaucoma

Start: 2016-02-29End: 2017-03-31Updated: 2019-05-21

Related Papers

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

Advances in Therapy2020-03-1284 citations

Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.

2020-01-2414 citations